How to Interpret Kirby-Bauer Zone Diameters Using CLSI Breakpoints

The Kirby-Bauer disk diffusion test (also known as the Bauer-Kirby test) is a standardized method for determining the susceptibility of a bacterial isolate to antimicrobial agents. Interpretation of the resulting zone of inhibition diameters is performed by comparing measured zone sizes against published clinical breakpoints, most commonly those established by the Clinical and Laboratory Standards Institute (CLSI). This article provides a practical guide to accurately measuring inhibition zones, applying current CLSI breakpoints, and correctly categorizing results as Susceptible (S), Intermediate (I), or Resistant (R) for common BSL-1 organisms. This guide is intended for educational and research settings using routine BSL-1 teaching laboratory protocols and does not cover clinical diagnostic workflows or pathogen propagation.

At a Glance: Key Steps in Kirby-Bauer Zone Interpretation

Scientific Principle of the Kirby-Bauer Test

The Kirby-Bauer disk diffusion method relies on the diffusion of a standardized concentration of an antimicrobial agent from a paper disk into an agar medium. As the antimicrobial diffuses, a concentration gradient is established, with the highest concentration nearest the disk. After incubation, the bacterial growth is inhibited where the antimicrobial concentration exceeds the minimum inhibitory concentration (MIC) for that organism. The resulting clear zone around the disk—the zone of inhibition—is measured in millimeters. The diameter of this zone is inversely related to the MIC: larger zones indicate greater susceptibility (lower MIC), while smaller or absent zones indicate resistance (higher MIC).

The relationship between zone diameter and MIC is not linear but follows a predictable pattern established through rigorous testing by CLSI. Breakpoints are determined by correlating zone diameters with MIC values for large collections of bacterial isolates, incorporating pharmacokinetic and pharmacodynamic data, and considering clinical outcomes. This is why zone diameter interpretation must always be performed using validated breakpoints rather than arbitrary cutoffs.

Materials and Instrumentation Choices for Accurate Measurement

Measurement Tools

The accuracy of zone diameter interpretation begins with precise measurement. The following tools are commonly used:

• Manual calipers (digital or Vernier): Provide measurements to 0.1 mm precision. Digital calipers reduce reading errors and are preferred for research applications where data accuracy is critical.
• Ruler (transparent, with millimeter markings): Acceptable for routine teaching laboratories. Place the ruler across the center of the zone and read the diameter at the widest point.
• Automated zone readers: Instruments such as the BIOMIC or Sirscan systems use camera-based imaging to measure zones automatically. These systems can achieve sub-millimeter precision and directly apply CLSI breakpoints for classification. A recent study using YOLO11n-based artificial intelligence demonstrated a Mean Absolute Error of 0.42 mm in zone diameter prediction compared to manual measurement, with a Categorical Agreement of 94.2% [3].

Agar Medium

Mueller-Hinton agar (MHA) is the standard medium for Kirby-Bauer testing. Key considerations include:

• Depth: Pour plates to a uniform depth of 4 mm (approximately 25 mL per 100 mm plate). Variations in depth alter diffusion rates and zone sizes.
• pH: The pH of MHA should be between 7.2 and 7.4 at room temperature. Deviations affect the activity of certain antibiotics (e.g., tetracyclines are less active at acidic pH).
• Cation content: MHA must contain appropriate concentrations of calcium and magnesium ions, as these affect the activity of aminoglycosides and tetracyclines. Commercial MHA formulations are standardized for this purpose.

Inoculum Standardization

The bacterial inoculum must be standardized to a 0.5 McFarland turbidity standard (approximately 1.5 × 10⁸ CFU/mL for most organisms). This is achieved using a spectrophotometer or a commercial turbidity standard. Under- or over-inoculation directly affects zone sizes: a heavier inoculum produces smaller zones, potentially leading to false resistance classification.

Controls: The Foundation of Reliable Interpretation

Quality Control Strains

Each batch of tests must include quality control (QC) strains with known susceptibility patterns. For BSL-1 teaching laboratories, the following ATCC strains are commonly used:

• Escherichia coli ATCC 25922: A standard QC strain for disk diffusion testing. Zone diameter ranges for each antibiotic are published in CLSI M100.
• Staphylococcus aureus ATCC 25923: Used for QC of disks tested against Gram-positive organisms.
• Pseudomonas aeruginosa ATCC 27853: Used for QC of disks tested against non-fermenting Gram-negative rods.

QC results must fall within the published acceptable ranges for the test to be valid. If QC results are out of range, all patient or research isolate results from that batch are invalid and must be repeated.

Internal Controls

• Blank disk: Include a disk containing no antimicrobial agent to confirm that the medium supports growth and that inhibition is due to the antimicrobial, not the disk itself.
• Growth control: Ensure confluent lawn growth on the plate. Sparse growth or isolated colonies indicate an inadequate inoculum, and zones cannot be reliably interpreted.

Conceptual Workflow for Zone Diameter Interpretation

Step 1: Measure the Zone of Inhibition

After 16–18 hours of incubation at 35°C, examine each plate. For most organism-antimicrobial combinations, measure the diameter of the zone of complete inhibition, including the diameter of the disk. Use reflected light and hold the plate a few inches above a dark background to visualize the zone edge clearly.

Important exceptions:

• Trimethoprim-sulfamethoxazole: Measure the zone at the point of 80% inhibition, ignoring faint growth or thin film within the zone.
• Oxacillin and cefoxitin for MRSA screening: Look for any growth within the zone; even a single colony indicates resistance.
• Vancomycin for enterococci: Examine carefully for any growth within the zone; use transmitted light if necessary.

Step 2: Identify the Correct CLSI Breakpoint Table

CLSI breakpoints are organized by organism group and antimicrobial class. The major organism groups include:

• Enterobacterales (formerly Enterobacteriaceae)
• Pseudomonas aeruginosa
• Staphylococcus spp.
• Enterococcus spp.
• Streptococcus spp.
• Acinetobacter spp.

For each group, CLSI provides specific breakpoint tables. Using the wrong table is a common source of error. For example, breakpoints for ciprofloxacin differ between Enterobacterales and Pseudomonas aeruginosa.

Step 3: Compare Measured Diameter to Breakpoint Values

CLSI breakpoints are published as three values for each antimicrobial-organism combination:

• Susceptible (S): Zone diameter ≥ X mm
• Intermediate (I): Zone diameter between Y and Z mm
• Resistant (R): Zone diameter ≤ W mm

For example, for ciprofloxacin against Enterobacterales (CLSI M100, 34th edition):

• S: ≥ 26 mm
• I: 22–25 mm
• R: ≤ 21 mm

Step 4: Record the Categorical Result

Document the result as S, I, or R. The Intermediate category indicates that the antimicrobial may be effective at higher doses or at body sites where the drug concentrates. In research settings, the Intermediate category is often grouped with Resistant for prevalence calculations, but this should be explicitly stated in the methods.

Step 5: Interpret and Report

Compare results to expected susceptibility patterns for the organism. Unexpected resistance patterns (e.g., an E. coli isolate resistant to both ceftriaxone and ciprofloxacin) should be noted and may warrant repeat testing or confirmation by an alternative method.

Quality Checks and Validation

Verification of Breakpoint Currency

Using outdated CLSI breakpoints is a significant source of interpretive error. A retrospective study analyzing 9,279 bacterial isolates found that implementation of outdated breakpoints led to substantial misclassification of susceptibility [2]. For example, gentamicin susceptibility distribution showed a significant shift when updated breakpoints were applied (χ² = 95.27, p < 0.0001), and piperacillin-tazobactam breakpoint changes for Pseudomonas aeruginosa resulted in significant reclassification (χ² = 6.62, p = 0.0366) [2].

Action: Always verify that you are using the most current CLSI M100 edition. CLSI updates breakpoints annually, and changes can be substantial. For research applications, document the specific edition used.

Zone Diameter Precision

Measure zones to the nearest millimeter. For research applications, consider using digital calipers or automated readers to improve precision. The correlation between manual and automated measurements is high (R² = 0.98) [3], but automated systems reduce inter-operator variability.

Edge Cases in Zone Reading

• Swarming organisms (e.g., Proteus spp.): Measure the zone at the edge of the swarming growth, not the edge of the individual colonies.
• Haemophilus influenzae: Requires supplemented MHA (with hemin and NAD) and incubation in 5% CO₂.
• Anaerobic bacteria: Require Brucella blood agar and anaerobic incubation; breakpoints are published in CLSI M11.

Result Interpretation: From Zone Diameter to Clinical Category

Understanding the Susceptible, Intermediate, and Resistant Categories

• Susceptible (S): The bacterial isolate is inhibited by the concentration of the antimicrobial that is achievable at the site of infection using standard dosing regimens. Treatment with that antimicrobial is likely to be effective.
• Intermediate (I): The bacterial isolate may be inhibited by higher-than-standard doses of the antimicrobial, or the drug may concentrate at certain body sites (e.g., urine, bile). This category serves as a buffer zone to prevent minor technical errors from causing major interpretive shifts.
• Resistant (R): The bacterial isolate is not inhibited by achievable concentrations of the antimicrobial. Treatment with that antimicrobial is unlikely to be effective.

Interpreting Results for Research Purposes

In research settings, particularly in epidemiological studies, the choice of breakpoint can significantly affect prevalence estimates. A study comparing CLSI breakpoints, epidemiological cut-offs (ECOFFs), and normalized resistance interpretation (NRI) breakpoints for E. coli isolates from poultry found that prevalence estimates for ceftazidime resistance ranged from 1.7% using CLSI breakpoints to 45.8% using ECOFFs [1]. This highlights the importance of clearly stating the breakpoint system used and understanding that different breakpoints answer different questions: CLSI breakpoints predict clinical outcome, while ECOFFs detect emerging resistance mechanisms.

Organism-Specific Interpretation Considerations

Enterobacterales:

• Third-generation cephalosporin resistance (ceftriaxone, ceftazidime, cefotaxime) may indicate extended-spectrum beta-lactamase (ESBL) production.
• Carbapenem resistance (ertapenem, meropenem, imipenem) requires confirmation by MIC methods.

Staphylococcus aureus:

• Cefoxitin disk (30 μg) is used for MRSA screening. Zone diameter ≤ 21 mm indicates mecA-mediated resistance.
• Linezolid breakpoints were revised in the 34th edition of CLSI M100, introducing an intermediate category that resulted in significant reclassification from susceptible to intermediate (χ² = 17.45, p = 0.00016) [2].

Pseudomonas aeruginosa:

• Piperacillin-tazobactam breakpoints were revised, leading to significant reclassification of isolates [2].
• Tobramycin breakpoints also showed significant shifts with updated CLSI guidelines (χ² = 77.94, p < 0.0001) [2].

Acinetobacter baumannii:

• Tetracycline and its derivatives (doxycycline, minocycline, tigecycline) are alternative agents for carbapenem-resistant strains. A study of carbapenem-resistant A. baumannii found tigecycline susceptibility at 99% and colistin at 98% using CLSI breakpoints [4].

Achromobacter spp.:

• These organisms have no established CLSI clinical breakpoints for disk diffusion [5]. Interpretation must be approached with caution, and MIC methods are preferred for these organisms.

Troubleshooting Common Interpretation Issues

Limitations of Kirby-Bauer Zone Diameter Interpretation

Method-Specific Limitations

1. Qualitative nature: The Kirby-Bauer test provides categorical results (S, I, R) but does not provide an MIC value. For research applications requiring quantitative data, MIC methods (broth microdilution or agar dilution) are preferred.

2. Organism restrictions: Not all organisms grow sufficiently on MHA to produce reliable zones. Fastidious organisms (e.g., Haemophilus, Neisseria, Streptococcus pneumoniae) require supplemented media and specific incubation conditions.

3. Antimicrobial restrictions: Some antimicrobials do not diffuse well in agar and cannot be tested by disk diffusion (e.g., daptomycin requires calcium-supplemented medium; fosfomycin requires glucose-6-phosphate supplementation).

4. Breakpoint availability: Not all organism-antimicrobial combinations have established CLSI breakpoints. For example, Achromobacter spp. lack clinical breakpoints for disk diffusion [5], and interpretation must rely on MIC methods or published epidemiological cut-offs.

Interpretation Limitations

1. Breakpoint variability: Different breakpoint systems (CLSI, EUCAST, ECOFFs, NRI) can yield different prevalence estimates for the same dataset [1]. Researchers must clearly state which system was used and justify their choice.

2. Outdated breakpoints: Delayed implementation of updated CLSI breakpoints results in significant misclassification of antimicrobial susceptibility, leading to overestimation of susceptibility and masking emerging resistance [2].

3. Intermediate category ambiguity: The clinical significance of the Intermediate category varies by drug and infection site. In research, the Intermediate category is often grouped with Resistant, but this practice should be explicitly stated.

Documentation Requirements

Essential Documentation for Research Records

For each Kirby-Bauer test, document the following:

1. Organism identification: Species and source of isolate
2. Inoculum preparation: McFarland standard used, method of standardization
3. Medium: Type, lot number, expiration date, depth
4. Antimicrobial disks: Drug name, disk concentration, manufacturer, lot number, expiration date
5. Incubation conditions: Temperature, atmosphere, duration
6. QC results: Zone diameters for QC strains, comparison to CLSI acceptable ranges
7. Breakpoint source: CLSI M100 edition and year
8. Zone diameters: Measured to nearest millimeter for each antimicrobial
9. Interpretation: S, I, or R for each antimicrobial
10. Any deviations from standard protocol: Including reasons and potential impact on results

Data Management

Record zone diameters in a laboratory notebook or electronic database. For research studies, consider using a Laboratory Information Management System (LIMS) to track results and facilitate data analysis. Automated zone readers can export data directly to spreadsheets or databases, reducing transcription errors.

Biosafety Considerations for BSL-1 Teaching Laboratories

Risk Assessment

The Kirby-Bauer test is performed with bacterial isolates that have been characterized as BSL-1 organisms (e.g., E. coli K-12, non-pathogenic strains of S. aureus). According to the Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Edition, BSL-1 is appropriate for work with agents not known to consistently cause disease in healthy adults [6].

Standard Microbiological Practices

1. Hand washing: Before and after handling cultures
2. Personal protective equipment: Lab coat, gloves, and eye protection
3. Decontamination: All waste (plates, swabs, disks) must be autoclaved before disposal
4. Work surface decontamination: Before and after each session with 10% bleach or appropriate disinfectant
5. No eating, drinking, or applying cosmetics in the laboratory
6. Mechanical pipetting only: No mouth pipetting

Specific Precautions for Disk Diffusion Testing

• Aseptic technique: Use sterile loops, swabs, and forceps for disk placement
• Disk dispenser maintenance: Clean disk dispensers regularly to prevent cross-contamination
• Incubation: Plates should be incubated in sealed containers or bags to prevent contamination of incubators
• Reading plates: Do not open plates after incubation; read through the lid

Recombinant or Synthetic Nucleic Acid Considerations

If the bacterial isolates used in Kirby-Bauer testing contain recombinant or synthetic nucleic acid molecules, the work must be conducted in accordance with the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules [7]. This may require Institutional Biosafety Committee (IBC) approval and additional containment measures.

Frequently Asked Questions

1. Why do zone diameters for the same antibiotic differ between organism groups?

CLSI breakpoints are organism-specific because the relationship between zone diameter and MIC varies by organism. Factors such as growth rate, inoculum effect, and intrinsic resistance mechanisms affect how an organism responds to an antimicrobial in the disk diffusion test. For example, the breakpoint for ciprofloxacin against Enterobacterales (S ≥ 26 mm) differs from that against Pseudomonas aeruginosa (S ≥ 25 mm) because the pharmacokinetic and pharmacodynamic targets differ between these organisms. Always consult the organism-specific table in CLSI M100.

2. Can I use Kirby-Bauer results to determine MIC values?

No. The Kirby-Bauer test provides a categorical result (S, I, or R) but does not directly provide an MIC value. While there is an inverse correlation between zone diameter and MIC, the relationship is not linear enough to accurately predict MIC from a single zone measurement. For quantitative MIC data, use broth microdilution or agar dilution methods. Some automated systems can estimate MIC from zone diameters using regression analysis, but these estimates should be confirmed by reference methods.

3. How often should I update my CLSI breakpoint tables?

CLSI updates the M100 document annually. You should update your breakpoint tables with each new edition, as changes can be substantial. A study found that delayed implementation of updated breakpoints led to significant misclassification of susceptibility, particularly for aminoglycosides, piperacillin-tazobactam, and linezolid [2]. For research applications, document the specific edition used and note any changes from previous editions that might affect data comparability.

4. What should I do if my QC strain results are out of the acceptable range?

If QC results fall outside the published acceptable ranges, all test results from that batch are invalid. Do not report or use any results until the issue is resolved. Common causes include: expired or improperly stored disks, incorrect medium pH or depth, inoculum standardization errors, or incubation temperature deviations. Troubleshoot systematically: test a new lot of disks, prepare fresh MHA plates, verify the McFarland standard, and confirm incubation conditions. Document all corrective actions taken.

References and Further Reading

1. Maganga R, Sindiyo E, Musyoki VM, Shirima G, Mmbaga BT. Comparative analysis of clinical breakpoints, normalized resistance interpretation and epidemiological cut-offs in interpreting antimicrobial resistance of Escherichia coli isolates originating from poultry in different farm types in Tanzania. 2023. PubMed. https://pubmed.ncbi.nlm.nih.gov/37601443/

2. Goyal N, Gangar S, Ramakrishnan B, Goma M, Sj G, Das S. Impact of Outdated Clinical and Laboratory Standards Institute (CLSI) Breakpoint Implementation on Antimicrobial Susceptibility Interpretation: A Retrospective Analytical Study. 2026. PubMed. https://pubmed.ncbi.nlm.nih.gov/41913829/

3. Ciftci F, Erarslan A, Rahebi J. Automatic detection and quantification of antimicrobial inhibition zones using YOLO11n with post-hoc interpretability validation. 2026. PubMed. https://pubmed.ncbi.nlm.nih.gov/42131204/

4. Ahsan M, Adnan F, Khan MA, Khursheed N. Antimicrobial susceptibility of carbapenem-resistant Acinetobacter baumannii against tetracycline, doxycycline, tigecycline, minocycline and colistin: experience from a tertiary care hospital in Karachi. 2026. PubMed. https://pubmed.ncbi.nlm.nih.gov/41491984/

5. Ray S, Flemming LK, Scudder CJ, Ly MA, Porterfield HS, Smith RD, Clark AE, Johnson JK, Das S. Comparative phenotypic and genotypic antimicrobial susceptibility surveillance in Achromobacter spp. through whole genome sequencing. 2025. PubMed. https://pubmed.ncbi.nlm.nih.gov/40013782/

6. CDC and NIH. Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Edition. U.S. Department of Health and Human Services. 2020. https://www.cdc.gov/labs/bmbl/index.html

7. National Institutes of Health. NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. NIH Office of Science Policy. https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules/

8. National Center for Biotechnology Information. NCBI Bookshelf: Molecular Biology and Laboratory Methods. https://www.ncbi.nlm.nih.gov/books/

Related Articles

• How to Perform a Kirby-Bauer Disk Diffusion Susceptibility Test: Protocol and Interpretation
• How to Interpret a Calibration Certificate for Laboratory Instruments
• How to Interpret Colony Morphology on Agar Plates
• How to Interpret Gram Stain Results: Morphology, Arrangement, and Color
• How to Calculate Bacterial Colony-Forming Units (CFU) per mL from a Spread Plate
• How to Calculate the Minimum Inhibitory Concentration (MIC) from Broth Microdilution Data